RxDoctor Payments Data

Erik Bowman, MD

Gastroenterology · Lincoln, NENPI 1942434659

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,326 of the $3,062 with a category attached, or 76.0%. Boston Scientific accounts for 66.1% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $1,322 and has fallen 76.7% since, to $308 in 2025.

$3,062in general payments, 2019–2025

Across 57 payments — averaging $53.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Johnson & Johnson$305
  • Aimmune Therapeutics, Inc.$181
  • Olympus America Inc.$156
  • AbbVie$121
  • Zimmer Biomet$104
  • plus $172 from 6 others

What the payments were for

  • Travel & lodging$73524%
  • Food & beverage$2,32676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,062 in reported general payments places this provider in the 55th percentile of 89 gastroenterology providers in Nebraska.

See all gastroenterology providers in Nebraska

Medicare billing

Part B allowed, 2024
$282,428
Medicare patients
520
Services billed
7,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres13$59,134
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates280$17,882
LinzessLinaclotide12$6,193
Pantoprazole Sodium206$1,994
Lubiprostone12$1,488
Omeprazole113$1,459
Ondansetron Hcl18$978
Colestipol Hcl13$952
Esomeprazole Magnesium22$950
Azathioprine17$778
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl33$540
Dicyclomine Hcl48$487
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl24$434
Famotidine33$368
Sucralfate14$281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$121$6,19312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 89 gastroenterology providers in Nebraska.

Other gastroenterology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →